Qty	Catalog Number	Ordering Description	Qty/Pack	List Price
			96-Well Plate

Qty	Catalog Number	Ordering Description	Qty/Pack	List Price
	48-602MAG	Buffer Detection Kit for Magnetic Beads	1 Kit

03-108 Sigma-AldrichRIPAb+ Fragile X Mental Retardation Protein - RIP Validated Antibody and Primer Set

This RIPAb+ Fragile X Mental Retardation Protein -RIP Validated Antibody & Primer Set conveniently includes the antibody & the specific control PCR primers.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Key Applications: RNA Binding Protein Immunoprecipitation (RIP), Western Blotting, ELISA, Immunocytochemistry, Immunohistochemistry, Immunohistochemistry (Paraffin), Immunoprecipitation Research Category: Epigenetics & Nuclear Function, Neuroscience Research Sub-Category: RNA Binding Protein (RBP), RNA Metabolism & Binding Proteins, Neurodegenerative Diseases

View Products on Sigmaaldrich.com

Recommended Products

Overview

Replacement Information

Special Offers

100% Performance Guaranteed

Key Specifications Table

Species Reactivity	Key Applications
H, M, R	RIP, WB, ELISA, ICC, IHC, IH(P), IP

Description
Catalogue Number	03-108
Brand Family	Upstate
Trade Name	RIPAb+ Upstate
Description	RIPAb+ Fragile X Mental Retardation Protein - RIP Validated Antibody and Primer Set
Overview	RIPAb+ antibodies are evaluated using the RNA Binding Protein Immunoprecipitation (RIP) assay. Each RIPAb+ antibody set includes a negative control antibody to ensure specificity of the RIP reaction and is verified for the co-immunoprecipitation of RNA associated specifically with the immunoprecipitated RNA binding protein of interest. Where appropriate, the RIPAb+ set also includes quantitative RT-PCR control primers (RIP Primers) to biologically validate your IP results by successfully co-precipitating the specific RNA targets, such as messenger RNAs. The qPCR protocol and primer sequences are provided, allowing researchers to validate RIP protocols when using the antibody in their experimental context. If a target specific assay is not provided, the RIPAb+ kit is validated using an automated microfluidics-based assay by enrichment of detectable RNA over control immunoprecipitation.
Alternate Names	Fragile X mental retardation 1 protein
Background Information	Fragile X Mental Retardation Protein (FMRP) is a RNA-binding protein that is associated to polysomes and may be involved in the transport of mRNA from the nucleus to the cytoplasm. Defects in FMR1 are the cause of Fragile X syndrome, which is a common genetic disease characterized by moderate to severe mental retardation, macroorchidism, large ears, prominent jaw, and high-pitched, jocular speech. The defect in most fragile X syndrome patients results from an amplification of a CGG repeat region which is directly in front of the coding region.

References

Product Information
Format	Purified
Control	Includes negative control mouse IgG antibody and control primers specific for mouse Iqsec1.
Presentation	Anti-Fragile X Mental Retardation Protein (Mouse Monoclonal IgG1κ). One vial containing 50 μL of liquid, does not contain any preservative. Store at -20°C. Normal Mouse IgG. One vial containing 125 μg of purified mouse IgG in 125 µL of storage buffer containing 0.1% sodium azide. Store at -20°C. RIP Primers, Iqsec1. One vial containing 75 μL of 5 μM of each primer specific for mouse Iqsec1. Store at -20°C. FOR: GCG TCT AGG ACC TTG TGA GC REV: GAA GGC TGA CCT CCA TGT TG
Quality Level	MQ100

Applications
Application	This RIPAb+ Fragile X Mental Retardation Protein -RIP Validated Antibody & Primer Set conveniently includes the antibody & the specific control PCR primers.
Key Applications	RNA Binding Protein Immunoprecipitation (RIP) Western Blotting ELISA Immunocytochemistry Immunohistochemistry Immunohistochemistry (Paraffin) Immunoprecipitation
Application Notes	Western Blot Analysis: Representative lot data. Mouse E17 spinal cord lysate (Lane 1), Mouse E16 brain (Lane 2) and NIH/3T3 lysate (Lane 3) were resolved by electrophoresis, transferred to PVDF membrane and probed with anti-Fragile X Mental Retardation Protein (1:500 dilution of a previous lot). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and a chemiluminescence detection system. Arrow indicates Fragile X Mental Retardation Protein (~71 kDa) (Please see figures). Immunohistochemistry: Frozen and paraffin sections. 1:500-1:5,000 dilution of a previous lot was used. ELISA: A 1:500-1:5,000 dilution of a previous lot was used in ELISA. Detection of FMRP on Blood Smears: A 1:500-1:5,000 dilution of a previous lot was used. Immunocytochemistry: A 1:500-1:5,000 dilution of a previous lot was used on transfected cells. Light fixation (2% PFA, permeabilize with 0.1% triton in block only) (Please see figures). Optimal working dilutions must be determined by the end user.

Biological Information
Immunogen	Fusion protein with a full length FMRP (human).
Host	Mouse
Specificity	FMRP. Cross reaction with FXR protein may be detected in cases of high expression in mice.
Isotype	IgG1κ
Species Reactivity	Human Mouse Rat
Antibody Type	Monoclonal Antibody
Entrez Gene Number	NP_002015.1
Entrez Gene Summary	The protein encoded by this gene binds RNA and is associated with polysomes. The encoded protein may be involved in mRNA trafficking from the nucleus to the cytoplasm. A trinucleotide repeat (CGG) in the 5' UTR is normally found at 6-53 copies, but an expansion to 55-230 repeats is the cause of fragile X syndrome.
Gene Symbol	FMR1 FMRP
UniProt Number	Q06787
UniProt Summary	FUNCTION: SwissProt: Q06787 # RNA-binding protein. Associated with polysomes and might be involved in the transport of mRNA from the nucleus to the cytoplasm. Binds strongly to poly(G), binds moderately to poly(U) but shows very little binding to poly(A) or poly(C). SIZE: 632 amino acids; 71174 Da SUBUNIT: Found in a RNP granule complex with IGF2BP1. Interacts with FXR1, FXR2, IGF2BP1, NUFIP1 and RANBP9. Interacts with CYFIP1 and CYFIP2. SUBCELLULAR LOCATION: Cytoplasm. Nucleus. TISSUE SPECIFICITY: Highest levels found in neurons, brain, testis, placenta and lymphocytes. Also expressed in epithelial tissues and at very low levels in glial cells. DISEASE: SwissProt: Q06787 # Defects in FMR1 are the cause of fragile X syndrome. [MIM:300624]. It is a common genetic disease (has a prevalence of one in every 2000 children) which is characterized by moderate to severe mental retardation, macroorchidism (enlargement of the testicles), large ears, prominent jaw, and high-pitched, jocular speech. The defect in most fragile X syndrome patients results from an amplification of a CGG repeat region which is directly in front of the coding region. & Defects in FMR1 are the cause of fragile X tremor/ataxia syndrome (FXTAS) [MIM:300623]. In FXTAS, the expanded repeats range in size from 55 to 200 repeats and are referred to as 'premutations'. Full repeat expansions with greater than 200 repeats results in fragile X mental retardation syndrome [MIM:300624]. Carriers of the premutation typically do not show the full fragile X syndrome phenotype, but comprise a subgroup that may have some physical features of fragile X syndrome or mild cognitive and emotional problems. SIMILARITY: SwissProt: Q06787 ## Belongs to the FMR1 family. & Contains 2 KH domains. MISCELLANEOUS: RNA-binding activity is inhibited by RANBP9. & The mechanism of the severe phenotype in the Asn- 304 patient lies in the sequestration of bound mRNAs in nontranslatable mRNP particles. In the absence of FMRP, these same mRNAs may be partially translated via alternate mRNPs, although perhaps abnormally localized or regulated, resulting in typical fragile X syndrome. Asn-304 mutation maps to a position within the second KH domain of FMRP that is critical for stabilizing sequence-specific RNA-protein interactions. Asn-304 mutation abrogates the association of the FMRP KH 2 domain with its target, kissing complex RNA.
Molecular Weight	71 kDa

Physicochemical Information

Dimensions

Materials Information

Toxicological Information

Safety Information according to GHS

Safety Information

Product Usage Statements
Quality Assurance	RNA Binding Protein Immunoprecipitation: RIP Lysate prepared from NIH/3T3 cells (2 x 10⁷ cell equivalents per IP) were subjected to immunoprecipitation using 5 µL of either a normal mouse IgG or 5 µL of Anti-Fragile X Mental Retardation Protein antibody and the Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Cat. # 17-700). Successful immunoprecipitation of Fragile X Mental Retardation Protein-associated RNA was verified by qPCR using RIP Primers Iqsec1 (Please see figures). Please refer to the Magna RIP™ (Cat. # 17-700) or EZ-Magna RIP™ (Cat. # 17-701) protocol for experimental details.
Usage Statement	Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Product Usage Statements

Quality Assurance

RNA Binding Protein Immunoprecipitation:
RIP Lysate prepared from NIH/3T3 cells (2 x 10⁷ cell equivalents per IP) were subjected to immunoprecipitation using 5 µL of either a normal mouse IgG or 5 µL of Anti-Fragile X Mental Retardation Protein antibody and the Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Cat. # 17-700).
Successful immunoprecipitation of Fragile X Mental Retardation Protein-associated RNA was verified by qPCR using RIP Primers Iqsec1 (Please see figures).
Please refer to the Magna RIP™ (Cat. # 17-700) or EZ-Magna RIP™ (Cat. # 17-701) protocol for experimental details.

Usage Statement

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage and Shipping Information
Storage Conditions	Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Packaging Information
Material Size	10 assays
Material Package	10 assays per set. Recommended use: ~5 μL of antibody per RIP (dependent upon biological context).

Transport Information

Supplemental Information

Specifications

Global Trade Item Number
Catalog Number	GTIN
03-108	04053252679193

Documentation

RIPAb+ Fragile X Mental Retardation Protein - RIP Validated Antibody and Primer Set SDS

Title
Safety Data Sheet (SDS)

RIPAb+ Fragile X Mental Retardation Protein - RIP Validated Antibody and Primer Set Certificates of Analysis

Title	Lot Number
RIPAb+ Fragile X Mental Retardation Protein - 2140069	2140069
RIPAb+ Fragile X Mental Retardation Protein - 2433528	2433528
RIPAb+ Fragile X Mental Retardation Protein - 1967266	1967266
RIPAb+ Fragile X Mental Retardation Protein - 2210369	2210369
RIPAb+ Fragile X Mental Retardation Protein - 3171006	3171006
RIPAb+ Fragile X Mental Retardation Protein - 3290713	3290713
RIPAb+ Fragile X Mental Retardation Protein - 3660532	3660532
RIPAb+ Fragile X Mental Retardation Protein Monoclonal Antibody/Primer Set	3013680

Related Products & Applications

Related Products

Catalog Number	Description
MAB2160	Anti-Fragile X Mental Retardation Protein Antibody, clone 1C3
MABN1788	Anti-FMR1polyG Antibody, clone 9FM-1B7
MABN784	Anti-FMR1polyG Antibody, clone 2J7

The Product Has Been Added To Your Cart